Timing of Biologic Therapy Does Not Affect Short-Term response in Psoriatic Arthritis, Suggests Study

A new study published in the journal Arthritis Care & Research showed that short-term response to biologic therapy in psoriatic arthritis (PsA) appears similar whether treatment is started early or later in the disease course. However, whether early biologic treatment can prevent long-term joint damage and disease progression remains uncertain and requires further study.

Psoriatic arthritis is a long-term inflammatory condition that results in comorbidities, lower quality of life, joint degeneration, and disability. Although they have improved disease management, biologics that target TNF, IL-12/23, IL-23, and IL-17 are still expensive and have stringent eligibility requirements. A crucial "window of opportunity" may be lost if therapy is postponed since longer illness duration is linked to increased structural damage and disease burden. There is still little data that explicitly compares early vs. delayed biologic treatment, despite research supporting early intense therapy. This study assesses whether biologic-naive PsA patients' results are improved by starting biologics earlier.

The investigation comprised PsA patients who began biologic treatment between 2000 and 2025. If a patient began biologic therapy within two years of being diagnosed with PsA, they were placed in the early treatment group; if not, they were placed in the delayed treatment group. At six months, a ≥50% decrease in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score was the main result. Psoriasis Area and Severity Index (PASI) 75, which is defined as a ≥75% improvement in the PASI score at six months, was the secondary outcome. The relationship between early therapy and six-month disease outcomes was investigated using logistic regression. Differences between the groups at the baseline visit were taken into consideration using propensity scores.

Of the 228 patients that were enrolled, 157 were in the delayed treatment group and 71 were in the early treatment group. Over the decades, there were notable variations in the period from PsA diagnosis to biologic therapy. There was no discernible difference in response at 6 months between patients treated within two years of diagnosis and those treated later, according to the propensity score regression adjusted analysis.

Overall, patients who began therapy during the first two years of their illness did not vary from those who began therapy later in terms of the inflammatory response in joint and skin symptoms. This implies that regardless of the length of their illness or the amount of damage they have accumulated, PsA patients with active disease should begin treatment. Whether early therapy is beneficial for other outcomes, such as the accumulation of structural damage, quality of life, and function, is still up for debate.

Source:

Cho, S. M., Gao, S., Pereira, D., Cook, R. J., & Gladman, D. D. (2026). Short-term response to biologic therapy in Psoriatic Arthritis is not influenced by disease duration at initiation of therapy. Arthritis Care & Research, acr.80120. https://doi.org/10.1002/acr.80120